William Blair Keeps Their Buy Rating on Celyad (CYAD)

By Jason Carr

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Celyad (CYADResearch Report). The company’s shares closed last Monday at $12.54, close to its 52-week low of $10.19.

Prasad commented:

“We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially registration enabling) study regimen in 2020. Celyad in June presented updated data from dose level 3 (3e9 cells given in three biweekly infusions) and initial data from cohort 10 (1e9 cells at a dense schedule of three CY AD-01 weekly infusions) of the THINK study at the European Hematology Association (EHA) 2019 meeting (EHA With CY AD-01 Dense Schedule and Preconditioning Regimens).”

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 11.1% and a 45.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.

Celyad has an analyst consensus of Strong Buy, with a price target consensus of $44.50, representing a 273.3% upside. In a report released today, JonesTrading also reiterated a Buy rating on the stock with a $60 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32.18 and a one-year low of $10.19. Currently, Celyad has an average volume of 13.74K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.